Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy

Nanoscale Research Letters

Volumn 8, Issue 1, 2013, Pages 1-12

  Zheng, Yi ^a   Chen, Hongbo ^a   Zeng, Xiaowei ^a   Liu, Zhigang ^b   Xiao, Xiaojun ^b   Zhu, Yongqiang ^a   Gu, Dayong ^a,c   Mei, Lin ^a  

^a TSINGHUA UNIVERSITY   (China)

^b Shenzhen University   (China)

^c Yantian Entry exit Inspection and Quarantine Bureau   (China)

Author keywords

Cervical cancer; Endostatin; Gene delivery; Nanoparticles; TPGS b (PCL ran PGA); Trail

Indexed keywords

CELL DEATH; DISEASES; EMULSIFICATION; FLUORESCENCE MICROSCOPY; GENE THERAPY; GENE TRANSFER; LANTHANUM COMPOUNDS; MAMMALS; TUMORS;

CERVICAL CANCERS; ENDOSTATINS; GENE DELIVERY; TPGS-B-(PCL-RAN-PGA); TRAIL;

NANOPARTICLES;

MUS;

EID: 84878749247     PISSN: 19317573     EISSN: 1556276X     Source Type: Journal    
DOI: 10.1186/1556-276X-8-161     Document Type: Article

References (59)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
2. Ma Y, Huang L, Song C, Zeng X, Liu G, Mei L: Nanoparticle formulation of poly(ε-caprolactone-co-lactide)-d-α-tocopheryl polyethylene glycol 1000 succinate random copolymer for cervical cancer treatment. Polymer 2010, 51:5952-5959.
3. Schiller JT, Castellsague X, Villa LL, Hildesheim A: An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008, 26(Suppl 10):K53-K61.
4. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
5. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364:806-809.
6. Nagata S: Apoptosis by death factor. Cell 1997, 88:355-365.
7. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162.
8. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157-163.
9. Folkman J: Tumor angiogenesis: therapeutic implications. New Engl J Med 1971, 285:1182-1186.
10. Folkman J: Tumor angiogenesis and tissue factor. Nat Med 1996, 2:167-168.
11. Auerbach W, Auerbach R: Angiogenesis inhibition: a review. Pharmacol Therapeut 1994, 63:265-311.
12. Winlaw DS: Angiogenesis in the pathobiology and treatment of vascular and malignant diseases. Ann Thorac Surg 1997, 64:1204-1211.
13. Folkman J: Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg 2007, 42:1-11.
14. Folkman J: Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 2006, 312:594-607.
15. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007, 6:273-286.
16. Michael SO: Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 2007, 69:S64-S66.
17. Zhuang HQ, Yuan ZY: Process in the mechanisms of endostatin combined with radiotherapy. Cancer Lett 2009, 282(1):9-13.
18. Herbst RS, Lee AT, Tran HT, Abbruzzese JL: Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep 2001, 3:131-140.
19. Jia Y, Liu M, Cao L, Zhao X, Wu J, Lu F, Li Y, He Y, Ren S, Ju Y, Wang Y, Li Z: Recombinant human endostatin, Endostar, enhances the effects of chemo-radiotherapy in a mouse cervical cancer xenograft model. Eur J Gynaecol Oncol 2011, 32(3):316-324.
20. Wu Y, Yang L, Hu B, Liu JY, Su JM, Luo Y, Ding ZY, Niu T, Li Q, Xie XJ, Wen YJ, Tian L, Kan B, Mao YQ, Wei YQ: Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine. Anticancer Drugs 2005, 16(5):551-557.
21. Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH, Flotte TR, Gaspar HB, Grez M, Griesenbach U, Kaplitt MG, Ott MG, Seger R, Simons M, Thrasher AJ, Thrasher AZ, Ylä-Herttuala S: Progress and prospects: gene therapy clinical trials (part 1). Gene Ther 2007, 20:1439-1447.
22. Guinn BA, Mulherkar R: International progress in cancer gene therapy. Cancer Gene Ther 2008, 12:765-775.
23. Scherer L, Rossi JJ, Weinberg MS: Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther 2007, 14:1057-1064.
24. Androic I, Krämer A, Yan R, Rödel F, Gätje R, Kaufmann M, Strebhardt K, Yuan J: Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer 2008, 8:391.
25. Brun A, Albina E, Barret T, Chapman DA, Czub M, Dixon LK, Keil GM, Klonjkowski B, Le Potier MF, Libeau G, Ortego J, Richardson J, Takamatsu HH: Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems. Vaccine 2007, 26:6508-6528.
26. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM: Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine 2007, 3:173-183.
27. Geusens B, Lambert J, De Smedt SC, Buyens K, Sanders NN, Van Gele M: Ultradeformable cationic liposomes for delivery of small interfering RNA (siRNA) into human primary melanocytes. J Control Release 2009, 133:214-220.
28. Zhou J, Wu J, Hafdi N, Behr JP, Erbacher P, Peng L: PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun 2006, 22:2362-2364.
29. Park TG, Jeong JH, Kim SW: Current status of polymeric gene delivery systems. Adv Drug Deliv Rev 2006, 58:467-486.
30. Son S, Kim WJ: Biodegradable nanoparticles modified by branched polyethylenimine for plasmid DNA delivery. Biomaterials 2010, 31:133-143.
31. Blum JS, Saltzman WM: High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine. J Control Release 2008, 129:66-72.
32. Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate TD, Klatzmann D, Lassmann H, Castro MG, Löwenstein PR: Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus mediated gene therapy: implications for clinical trials. Nat Med 1999, 11:1256-1263.
33. Huang H, Yu H, Tang G, Wang Q, Li J: Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. Biomaterials 2010, 31(7):1830-1838.
34. Haase R, Argyros O, Wong SP, Harbottle RP, Lipps HJ, Ogris M, Magnusson T, Vizoso Pinto MG, Haas J, Baiker A: pEPito: a significantly improved nonviral episomal expression vector for mammalian cells. BMC Biotechnol 2010, 10:20.
35. Halama A, Kuliński M, Librowski T, Lochyński S: Polymer-based non-viral gene delivery as a concept for the treatment of cancer. Pharmacol Rep 2009, 61(6):993-999.
36. Keeney M, van den Beucken JJ, van der Kraan PM, Jansen JA, Pandit A: The ability of a collagen/calcium phosphate scaffold to act as its own vector for gene delivery and to promote bone formation via transfection with VEGF (165). Biomaterials 2010, 31(10):2893-2902.
37. Mei L, Jin X, Song C, Wang M, Levy RJ: Immobolization of gene vector on polyurethane using monoclonal antibody for localized gene delivery. J Gene Med 2006, 8:690-698.
38. Jin X, Mei L, Song C, Liu L, Leng X, Sun H, Kong D, Levy RJ: Immobilization of plasmid DNA on anti-DNA antibody modified coronary stent for intravascular site-specific gene therapy. J Gene Med 2008, 10(4):421-429.
39. Uchimura E, Yamada S, Uebersax L, Fujita S, Miyake M, Miyake J: Method for reverse transfection using gold colloid as a nano-scaffold. J Biosci Bioeng 2007, 103(1):101-103.
40. Hauck TS, Ghazani AA, Chan WC: Assessing the effect of surface chemistry on gold nanorod uptake, toxicity, and gene expression in mammalian cells. Small 2008, 4(1):153-159.
41. Huang L, Chen H, Zheng Y, Song X, Liu R, Liu K, Zeng X, Mei L: Nanoformulation of d-.alpha;-tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran-glycolide) diblock copolymer for breast cancer therapy. Integr Biol 2011, 3:993-1002.
42. Andersen MØ, Lichawska A, Arpanaei A, Rask Jensen SM, Kaur H, Oupicky D, Besenbacher F, Kingshott P, Kjems J, Howard KA: Surface functionalisation of PLGA nanoparticles for gene silencing. Biomaterials 2010, 31(21):5671-5677.
43. Kakade S, Manickam DS, Handa H, Mao G, Oupický D: Transfection activity of layer-by-layer plasmid DNA/poly(ethylenimine) films deposited on PLGA microparticles. Int J Pharm 2009, 365:44-52.
44. Matsumoto A, Kitazawa T, Murata J, Horikiri Y, Yamahara H: A novel preparation method for PLGA microspheres using non-halogenated solvent. J Control Release 2008, 129:223-227.
45. Chumakova OV, Liopo AV, Andreev VG, Cicenaite I, Evers BM, Chakrabarty S, Pappas TC, Esenaliev RO: Composition of PLGA and PEI/DNA nanoparticles improves ultrasound-mediated gene delivery in solid tumor in vivo. Cancer Lett 2008, 261:215-225.
46. Zeng X, Sun YX, Qu W, Zhang XZ, Zhuo RX: Biotinylated transferrin/avidin/biotinylated disulfide containing PEI bioconjugates mediated p53 gene delivery system for tumor targeted transfection. Biomaterials 2010, 31(17):4771-4780.
47. Peng L, Gao Y, Xue YN, Huang SW, Zhuo RX: Cytotoxicity and in vivo tissue compatibility of poly(amidoamine) with pendant aminobutyl group as a gene delivery vector. Biomaterials 2010, 31(16):4467-4476.
48. Beyerle A, Braun A, Merkel O, Koch F, Kissel T, Stoeger T: Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice. J Control Release 2011, 151(1):51-56.
49. Sun H, Mei L, Song C, Cui X, Wang P: The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials 2006, 27:1735-1740.
50. Collnot EM, Baldes C, Wempe MF, Kappl R, Hüttermann J, Hyatt JA, Edgar KJ, Schaefer UF, Lehr CM: Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm 2007, 4(3):465-474.
51. Zhang Z, Mei L, Feng SS: Vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicine. Nanomedicine 2012, 7(11):1645-1647.
52. Youk HJ, Lee E, Choi MK, Lee YJ, Chung JH, Kim SH, Lee CH, Lim SJ: Enhanced anticancer efficacy of alpha-tocopheryl succinate by conjugation with polyethylene glycol. J Control Release 2005, 107:43-52.
53. Constantinou C, Papas A, Constantinou AI: Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int J Cancer 2008, 123(4):739-752.
54. Neuzil J, Tomasetti M, Zhao Y, Dong LF, Birringer M, Wang XF, Low P, Wu K, Salvatore BA, Ralph SJ: Vitamin E analogs, a novel group of "mitocans", as anticancer agents: the importance of being redox-silent. Mol Pharmacol 2007, 71(5):1185-1199.
55. Kim JH, Park JS, Yang HN, Woo DG, Jeon SY, Do HJ, Lim HY, Kim JM, Park KH: The use of biodegradable PLGA nanoparticles to mediate SOX9 gene delivery in human mesenchymal stem cells (hMSCs) and induce chondrogenesis. Biomaterials 2011, 32:268-278.
56. Zhou S, Xu J, Yang H, Deng X: Synthesis and characterization of biodegradable poly(ε-caprolactone)-polyglycolide-poly(ethylene glycol) monomethyl ether random copolymer. Macromol Mater Eng 2004, 289:576-580.
57. Song CX, Sun HF, Feng XD: Microspheres of biodegradable block copolymer for long-acting controlled delivery of contraceptives. Polymer J 1987, 19:485-491.
58. Liu K, Kiran E: High-pressure solution blending of poly(ε-caprolactone) with poly(methyl methacrylate) in acetone plus carbon dioxide. Polymer 2008, 49:1555-1561.
59. Wang C, Ge Q, Ting D, Nguyen D, Shen HR, Chen J, Eisen HN, Heller J, Langer R, Putnam D: Molecularly engineered poly (ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat Mater 2004, 3:190-196.